Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Efficacy and safety of oral and inhalation commercial beta-glucan products: Systematic review of randomized controlled trials (CROSBI ID 261364)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Markovina, Nikolina ; Banjari, Ines ; Bučević Popović, Viljemka ; Jeličić Kadić, Antonija ; Puljak, Livia Efficacy and safety of oral and inhalation commercial beta-glucan products: Systematic review of randomized controlled trials // Clinical nutrition (Edinburgh), 39 (2020), 1; 40-48. doi: 10.1016/j.clnu.2019.01.003

Podaci o odgovornosti

Markovina, Nikolina ; Banjari, Ines ; Bučević Popović, Viljemka ; Jeličić Kadić, Antonija ; Puljak, Livia

engleski

Efficacy and safety of oral and inhalation commercial beta-glucan products: Systematic review of randomized controlled trials

Background & aims Beta-glucans are advertised as biologically active compounds, with various health claims. We aimed to summarize results about efficacy and safety of commercial oral and inhalation beta-glucan products on human health from randomized controlled trials (RCTs). Methods We conducted systematic review of RCTs. We searched MEDLINE, CENTRAL and ClinicalTrials.gov. Any commercial product, any types of participants and any health-related outcomes were eligible. Two authors independently screened studies and extracted data. Cochrane risk of bias tool was used. This review did not have any extramural funding. Registration: PROSPERO record no. 42016043539. Results We included 30 RCTs that were conducted on healthy or ill participants. Most of the trials reported beneficial effect of beta- glucan, but among the 105 different outcome domains and measures that were used, only three could be considered clinically relevant, while others were various biomarkers and surrogate outcomes such as complete blood count. Included studies on average had 33 participants per study arm, high or unclear risk of bias of at least one domain, and only half of them reported data for safety. More than half of trials that reported source of funding indicated commercial sponsorship from producers of beta-glucan. Only five RCTs reported trial registration. Conclusions Commercial beta- glucan products were studied in a number of RCTs whose results can be considered only as preliminary, as they used small number of participants and surrogate outcomes. The quality of many studies was poor and further research and trials on bigger population should be performed before a final conclusion can be made.

beta-glucan ; systematic review ; evidence ; randomized controlled trial ; research waste

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

39 (1)

2020.

40-48

objavljeno

0261-5614

1532-1983

10.1016/j.clnu.2019.01.003

Povezanost rada

Javno zdravstvo i zdravstvena zaštita, Nutricionizam

Poveznice
Indeksiranost